Blodgett, Joanna M.
Pérez-Zepeda, Mario Ulisses
Godin, Judith
Kehler, Dustin Scott
Andrew, Melissa K.
Kirkland, Susan
Rockwood, Kenneth
Theou, Olga
Funding for this research was provided by:
Nova Scotia Health Research Foundation (MED-EST-2017-1241)
Canadian Institutes of Health Research (ACD-170302)
Article History
Received: 15 August 2023
Accepted: 22 December 2023
First Online: 6 January 2024
Declarations
:
: The opinions expressed in this manuscript are the author’s own and do not reflect the views of the Canadian Longitudinal Study on Aging. MKA reports grant funding from GSK, Sanofi, Pfizer, and the Canadian Frailty Network, and honoraria from Sanofi, Pfizer, and Seqirus, for work unrelated to the present study. KR asserts copyright of the Clinical Frailty Scale through Dalhousie University’s Industry, Liaison, and Innovation Office; is a co-founder of Ardea Outcomes (formerly DGI Clinical), which has had contracts with pharmaceutical and device manufacturers (Biogen, Shire, Hollister, Novartis, Nutricia, Roche, and Takeda) on individualized outcome measurement in the last 5 years; attended an advisory board meeting on dementia with Lundbeck in 2017; chaired a Scientific Workshop and Technical Review Panel on frailty for the Singapore National Research Foundation in 2020; received personal fees directly from event organizers for invited guest lectures, rounds, academic symposia, and presentations on frailty; and is an Associate Director of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes for Health Research, the Alzheimer Society of Canada, and several other charities.